Sign Up
OverviewAPI
Alector and GSK have initiated a Phase 2 clinical trial for AL101/GSK4527226, a promising drug targeting the sortilin receptor for Alzheimer's disease treatment. The trial aims to enroll around 282 patients globally and reflects Alector's commitment to developing potential treatments for neurodegenerative conditions, including Alzheimer's disease and frontotemporal dementia related to a progranulin gene mutation.

Ask a question